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Background: The survival benefits of adrenalectomy (ADx) in the setting of metastatic cancer and prognostic
factors for recurrence-free (RFS) and overall survival (OS) after adrenalectomy for metastatic carcinoma are still under
debate. We evaluated the impact of clinicopathological variables on RFS and OS after ADx for metastatic carcinoma
in patients with primary cancer.
Methods: A total of 32 patients undergoing ADx for metastatic cancer between 2004 and 2012 at two tertiary
medical centers. Metastases were regarded as synchronous (<6 months) or metachronous (≥6 months) depending
on the interval after primary surgery. Associations of perioperative clinicopathologic variables with RFS and OS were
analyzed using Cox regression models.
Results: In total, 32 patients received ADx for metastatic primary tumors located in the lung (n = 11), colon (n = 4),
liver (n = 5), stomach (n = 3), kidney (n = 4), pancreas (n = 2), glottis, esophagus, cervix, and ovary (n = 1 each).
The overall recurrence rate after adrenalectomy was 62.5% (n = 20). By univariate analysis, C-reactive protein,
inflammation-based prognosis score, and adrenalectomy for curative intent were associated with RFS and OS.
Independent prognostic factors for shorter RFS were operative method (laparoscopy HR 4.68, 95% CI 1.61-13.61,
p = 0.005) and inflammation-based prognostic score (HR 11.8, 95% CI 2.50-55.7, p = 0.002). For shorter OS, synchronous
metastasis (HR 3.05, 95% CI 1.07-11.94, p = 0.048) and inflammation-based prognostic score (HR 6.65, 95% CI 1.25-35.23,
p = 0.026) were identified as independent prognostic factors.
Conclusions: Our pilot study suggests that synchronous disease and inflammation-based prognostic score are significant
prognostic factors for survival and should be considered when performing ADx for metastatic diseases.
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The adrenal glands are a common site of metastases
from a variable primary cancer. Approximately 25% of
patients with primary cancer are found at autopsy to
have metastases to their adrenal glands [1]. Indeed, it
has been estimated that, in patients with a history of a
previous malignancy, over 50% of newly discovered ad-
renal lesions are metastatic [2].* Correspondence: kkangsung7@korea.ac.kr
4Department of Urology, Korea University School of Medicine, 73, Inchon-ro,
Seongbuk-gu, Seoul, Republic of Korea
Full list of author information is available at the end of the article
© 2014 Hwang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Advances in oncological and surgical therapies have
led to a significant increase in the life expectancy of can-
cer patients and have also prolonged survival of patients
with isolated or multiple metastases. Although the over-
all prognosis for metastatic cancer in the adrenal glands
is poor, the survival duration is longer in patients who
undergo adrenalectomy for metastatic cancer in com-
parison to that in patients who undergo resection of me-
tastases in other visceral sites, such as the liver and lung,
because adrenal metastasis is often confined within the
adrenal gland itself, providing more chances to achieve
en bloc removal [3-6]. It seems reasonable to apply simi-
lar criteria for selecting patients for resection of adrenalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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reasonably long disease-free interval, an acceptable pa-
tient performance status, and the absence of significant
comorbidity [2]. In this regard, several studies have re-
ported survival benefits of adrenalectomy (ADx) in the
setting of metastatic cancer [7,8] Nevertheless, the prog-
nostic factors for recurrence-free (RFS) and overall sur-
vival (OS) after adrenalectomy for metastatic carcinoma
are still under debate [8-11]. Therefore, we evaluated the
impacts of clinicopathological variables on the RFS and




At two tertiary medical centers in Korea (Chonnam
National University Hwasun Hospital and Korea University
Anam Hospital), a total of 32 patients received ADx for
metastasis to the adrenal gland, irrespective of the pri-
mary cancer type, between January 2004 and December
2012. Clinical indicated metastasis was evaluated using a
combination of endoscopy, computed tomographic scans
of the chest and abdomen, and positron emission tom-
ography or bone scans. The criteria for inclusion in the
present study of ADx for adrenal metastasis were as fol-
lows: (1) histologically confirmed primary cancer and ad-
renal metastasis; (2) presence of synchronous (primary
diagnosis to adrenalectomy less than six months) or
metachronous (primary diagnosis to adrenalectomy more
than six months) adrenal metastasis. Patients with renal
cell carcinoma (RCC) with synchronous adrenal metasta-
sis (ipsilateral or contralateral) or direct invasion of a pri-
mary cancer in the adrenal gland were excluded. Intent
to treat was divided into cure and palliation. Cure was
defined as a curative margin-negative (R0) resection with
no evidence of residual tumor at another site. Palliation
was defined as a surgical resection for symptom relief or
margin-positive (R1) resection with no evidence of
residual tumor at another site. Data regarding patient
demographics, RFS and OS were obtained by medical
record review. The recommendations of the Declaration
of Helsinki for biomedical research involving human sub-
jects were followed throughout. The study protocol was
reviewed by the Institutional Review Board of Chonnam
National University Hwasun Hospital and Korea Univer-
sity Anam Hospital and they waived the need for ethical
approval in both institutions.
Measurement of serum CRP and definition of Glasgow
Prognostic Score (GPS)
Routine laboratory testing of serum CRP and albumin
was performed before ADx. Serum CRP was measured
by latex turbidimetric immunoassay using a HITACHI
7600 analyzer (Hitachi, Tokyo, Japan). The CRP limit ofdetection was 0.03 mg/dl, and 1.0 mg/dl was the upper
limit of the normal range. Coefficients of variation over
the range of measurements were < 5%.
Each GPS was assigned as follows: patients with both
elevated CRP (>1.0 mg/dl) and low albumin (<3.5 mg/dl)
received a score of 2, whereas those with only one or
none of these biochemical abnormalities earned scores
of 1 and 0, respectively.
Statistics
Univariate and multivariate analyses (stepwise forward
procedure) were performed using Cox proportional haz-
ard analysis to identify risk factors affecting overall sur-
vival (OS) and recurrence-free survival (RFS). OS was
defined as the period from ADx to the date of death
from any cause. RFS was defined as the period from
ADx to the date of disease progression or death, which-
ever occurred first. If neither event had occurred at the
time of the last record, the patient was censored at that
time. The factors included in the model were age, sex,
ECOG PS, operative method (open or laparoscopic), in-
tent to treat (palliation or cure), interval of primary diag-
nosis to adrenalectomy (synchronous vs. metachronous),
site of metastasis, site of primary tumor, previous metas-
tasectomy, C-reactive protein, serum albumin, and GPS.
Among the factors, those with p < 0.25 were selected
(on univariate analysis for RFS and OS) and included
in the multivariate regression analysis using Cox pro-
portional hazards regression model, which was performed
to achieve adjusted hazard ratio (HR) to determine prog-
nostic factors for recurrence free and overall survival. A
two-tailed p < 0.05 was considered significant for all ana-
lyses. The SPSS software package, version 19.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis.
Results
Patient demographics
The baseline characteristics of the 32 patients are shown
in Table 1. The median patient age was 63.5 years
(range, 35–82 years). The median follow-up time (from
adrenalectomy to death or last follow-up date) was
10.4 months (range, 0.5-74.3 months), and median time
to adrenalectomy after primary cancer diagnosis was
8.8 months (range, 0–93.8 months). A total of 27 pa-
tients (84.4%) were male, and five patients (15.6%) were
female. Nineteen patients (59.4%) had synchronous ad-
renal metastasis and 13 had metachronous adrenal me-
tastasis. The diagnoses of primary cancer were lung
cancer (n = 11), liver cancer (n = 5), kidney cancer (n = 4),
colon cancer (n = 4), gastric cancer (n = 3), and glottis,
esophagus, pancreas, and ovary cancer (one each). The
median size of the largest metastatic adrenal tumor
was 3.5 cm, with a range of 1–10 cm. In 21 patients
(65.2%), CRP was elevated (>1 mg/dL), and 12 patients
Table 1 Baseline clinicopathological features of enrolled
patients
Variables




Size of metastasis (cm; median, range) 3.5 (1–10)
Interval: primary diagnosis to adrenalectomy
(months; median, range)
8.8 (0–93.8)
Intent to treat (%)
Palliative 10 (31.3)
Cure 22 (68.8)











Site of metastasis (%)
Single 14 (43.8)
Both 5 (15.6)




Interval: primary diagnosis to adrenalectomy (%)
≥6 months (metachronous) 13 (40.6)
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0, 1, and 2 were distributed evenly (31.3%, 34.4%, and
34.4%, respectively).
Surgical treatment and recurrence
The selection of surgical technique (open or laparoscopic)
depended on the individual surgeon. Laparoscopic ADx
was performed using a retroperitoneal approach. There
were no complications or mortalities related to ADx. Re-
currence after ADx was slightly high (62.5%).
Prognostic factors for RFS and OS
The median OS and RFS after ADx in enrolled patients
were 10.4 months (range, 0.5-74.3) and 7.3 months
(range, 0.5-74.3) respectively. Univariate analyses of the
clinicopathological parameters and RFS and OS are
shown in Table 2 and Table 3. In the univariate analysis,
ADx for cure was significantly associated with a better
OS (HR; 0.30 95% CI: 0.10-0.93, p = 0.038). RFS was not
associated with intent to treat (for cure, HR; 0.58, 95%
CI: 0.23-1.49, p = 0.265). C-reactive protein (>1 mg/dl)
showed a worse effect on RFS (HR; 7.55, 95% CI: 1.69-
33.6, p = 0.008) and OS (HR; 5.74, 95% CI: 1.24-26.5,
p = 0.025). The GPS (=2), together with C-reactive protein
and serum albumin level, showed a worse effect on RFS
(HR; 6.47, 95% CI: 1.64-25.3, p = 0.007) and OS (HR; 5.33,
95% CI: 1.09-26.0, p = 0.039). Multivariate regression ana-
lysis identified the independent negative prognostic factors
for OS and RFS (Tables 2 and 3). The independent negative
prognostic factors for OS were synchronous metastasis
(HR 3.05, 95% CI 1.07-11.94, p = 0.048) and GPS (HR 6.65,
95% CI 1.25-35.23, p = 0.026). The independent negative
prognostic factors for RFS were laparoscopic surgery (HR;
4.68, 95% CI: 1.61-13.61, p = 0.005) and GPS (=2, HR; 11.8,
95% CI: 2.50–55.7, p = 0.002).
Discussion
The adrenal glands are one of the most common sites
for metastasis, and the prevalence of isolated adrenal
metastasis has increased due to routine surveillance
of patients with known malignancy using radiologic ex-
aminations based on computed tomography, magnetic
Table 2 Univariate and multivariate analysis of variables affecting RFS
RFS (univariate analysis) RFS (multivariate analysis)
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age (>63.5 years) 1.84 (0.74-4.63) 0.19
Sex
Female 1 (reference)
Male 0.77 (0.24-2.38) 0.651
Operative method
Open 1 (reference) 1 (reference)
Laparoscopy 1.95 (0.78-4.87) 0.152 4.68 (1.61-13.61) 0.005
Intent to treat
Palliative 1 (reference)
Cure 0.58 (0.23-1.49) 0.265
Synchronous metastasis 1.95 (0.72-5.26) 0.186
Site of metastasis
Single 1 (reference)
Both 0.74 (0.15-3.56) 0.714
Adrenal + other site 1.02 (0.39-2.60) 0.967
Site of primary tumor
Other 1 (reference)
Liver 0.51 (0.11-2.24) 0.373
Stomach 0.15 (0.01-1.45) 0.103
Kidney 0.63 (0.11-3.58) 0.604
Lung 1.68 (0.57-4.94) 0.346
Previous metastasectomy
No 1 (reference)
Yes 0.33 (0.04-2.55) 0.294
C-reactive protein (mg/dl)
≤1.0 1 (reference)
>1 7.55 (1.69-33.6) 0.008
Albumin (g/dl)
≥3.5 1 (reference)
<3.5 2.03 (0.83-4.93) 0.118
GPS
0 1 (reference) 1 (reference)
1 2.82 (0.73-10.9) 0.132 2.77 (0.61-12.69) 0.189
2 6.47 (1.64-25.3) 0.007 11.80 (2.50-55.70) 0.002
ECOG-PS
0-1 1 (reference)
2 2.03 (0.65-6.32) 0.222
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[10,12-14]. Although small studies related to adrenalec-
tomy in the setting of metastasis have reported im-
proved survival, patients with adrenal metastasis are
frequently regarded as inoperable and have a poor progno-
sis [7,10,15]. Prognostic factors and surgical indicationsfor adrenalectomy have not been clearly defined, and
more series related to these patients in this setting are
needed.
Previously, Muth et al. reported the indication for ad-
renalectomy for adrenal metastasis with a consecutive
series of 30 patients, and the independent prognostic
Table 3 Univariate and multivariate analysis of variables affecting OS
OS (univariate analysis) OS (multivariate analysis)
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age (>63.5 years) 1.13 (0.37-3.46) 0.823
Sex
Female 1 (reference)
Male 2.56 (0.33-19.7) 0.367
Operative method
Open 1 (reference)
Laparoscopy 1.81 (0.62-5.29) 0.277
Intent to treat
Palliative 1 (reference)
Cure 0.30 (0.10-0.93) 0.038
Synchronous metastasis 2.15 (0.68-6.73) 0.187 3.05(1.07-11.94) 0.048
Site of metastasis
Single 1 (reference)
Both 0.60 (0.07-5.07) 0.64
Adrenal + other site 1.19 (0.39-3.61) 0.754
Site of primary tumor
Other 1 (reference)
Liver 0.35 (0.05-2.51) 0.301
Stomach 0.26 (0.02-2.87) 0.277
Kidney 0.63 (0.09-4.41) 0.648
Lung 1.41 (0.34-5.75) 0.626
Previous metastasectomy
No 1 (reference)
Yes 0.04 (0–67.8) 0.397
C-reactive protein (mg/dl)
≤1.0 1 (reference)
>1 5.74 (1.24-26.5) 0.025
Albumin (g/dl)
≥3.5 1 (reference)
<3.5 1.96 (0.68-5.61) 0.2
GPS
0 1 (reference) 1 (reference)
1 3.28 (0.60-17.8) 0.168 2.54 (0.46-14.26) 0.288
2 5.33 (1.09-26.0) 0.039 6.65 (1.25-35.23) 0.026
ECOG-PS
0-1 1 (reference)
2 1.81 (0.49-6.62) 0.368
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tential cure, no previous metastasis surgery, and tumor
type [9]. Vazquez et al. identified synchronous disease,
tumor type, size, burden, and site as risk factors for poor
prognosis in univariate analysis [10]. More recently,
Howell et al. suggested that prognostic factors includedsynchronous disease, a short disease-free interval (DFI),
and lung primary [16].
In our study, the independent negative prognostic fac-
tors for overall survival (OS) were synchronous metastasis,
and GPS. Synchronous metastasis was also an independent
prognostic factor in our study. With regard to synchronous
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a tumor presenting as a synchronous metastasis growing
faster or more aggressively and patients with metachro-
nous disease could be regarded as having more indolent
tumors [16]. With regard to the laparoscopic and open ap-
proach, the laparoscopic method could be a feasible option
even in aggressive tumor because we believe that our study
include the more aggressive tumor [17,18]. As mentioned
before, synchronous tumor and short disease-free interval
are related to more aggressive tumor, and overall survival
could reflect the tumor aggressiveness [9,10,16]. Tanvetya-
non et al. reported that the median overall survival was
shorter (~12 months) for patients with synchronous tumor
[8]. In our study, there were 19 synchronous patients
(59.4%), and the disease-free interval was 8.8 months. The
median overall survival was only 10.5 months. Muth et al.
reported nine patients (30%) with synchronous disease, a
median DFI of 26 months, and a median survival of
23 months [9]. Howell et al. described 11 synchronous pa-
tients (19%), a DFI > 12 months for 39 patients (81%), and
an overall median survival of 30 months [16]. Howell et al.
preferred open surgery in patients with multi-focal disease
and in patients with more aggressive tumor. In our study,
more aggressive patients were included, and the laparo-
scopic approach could be used in those patients in line
with results in previous studies. However, additional stud-
ies are needed to clarify this point.
In our study, GPS was selected as an independent poor
prognostic factor in multivariate analysis. GPS is based
on a combination of CRP and albumin and has been
evaluated in a variety of cancers, such as renal cancer,
breast cancer, non-small cell lung cancer, gastroesopha-
geal cancer, pancreatic cancer, and colorectal cancer
[19-24]. CRP is a sensitive marker of systemic inflamma-
tion, and elevated CRP concentrations are associated
with poorer survival in cancer patients, particularly in
patients with advanced disease [25]. The association with
elevated CRP levels and a dismal prognosis might reflect
the prognostic value of tumor produced interleukin-6,
an inducer of CRP production in the liver. Presurgical
CRP did correlate significantly with shorter RFS and OS
in univariate analysis as like other study. Albumin con-
centrations reflect both systemic inflammation and the
amount of lean tissue [25]. GPS, which is a combination
of CRP and albumin levels, reflects the effects of sys-
temic inflammatory response and the process of nutri-
tional decline in advanced cancer [26,27]. However, to
our knowledge, there has not been a study to evaluate
the prognostic significance in cancer patients with meta-
static adrenal lesion. Cancer cachexia and the ECOG
performance status have been mentioned as prognostic
factors, but ECOG performance status is recognized to
be subjective [28,29]. In our study, GPS had a prognostic
value superior to that of ECOG-PS. Mcmillan suggestedthat the GPS is a simple objective measure that can re-
flect cancer cachexia and predict outcome in patients
with cancer [29]. Furthermore, Lamb et al. reported that
an elevated GPS prior to surgery might be a useful prog-
nostic indicator in advanced renal cell carcinoma and
may alter the decision for surgery [30]. More research
will be needed to validate GPS as a risk factor in cancer
patients with adrenal metastasis.
Our study has a number of limitations. The study was
hampered by selection bias, and several variables are
inter-related because of the retrospective study design.
Furthermore, the number of patients was relatively small
for multivariate analysis, maybe due to this, there were
some discrepancies in the results. Hazard ratio (HR) of
both adrenal metastasis was lower than that of single
metastasis. Moreover, HR of the presence of previous
metastasectomy was lower than no history of previous
metastasectomy. In addition, heterogenous tumors are
included and malignant potential of primary tumor will
be the important factor for OS and RFS. However, the
number of each tumor type was not sufficient to assess
the prognostic value. Larger cohort study also is needed
to find out the prognostic value of the malignant poten-
tial of primary tumor.
Finally, our results were expressed with respect to the
outcomes of RFS and OS, rather than cancer specific
survival (CSS). Future studies of prognostic factors should
include CSS as an outcome measure.Conclusion
In our study, synchronous disease, operation method,
and inflammation-based prognostic score were significant
prognostic factors for survival associated with adrenalec-
tomy in cancer patients with adrenal metastatic diseases.
Synchronous metastasis was also a negative prognostic fac-
tor, which is in line with results from a previous study.
However, with regard to the operation method, further
study is necessary to establish the feasibility of adequate
outcomes with a laparoscopic approach in patients with
aggressive tumors. GPS appears to be superior to ECOG-
PS and could be a simple objective prognostic indicator,
but the baseline value of GPS prior to surgery needs to be
established in additional studies.Competing interests
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